Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Evangelos Karakitsios und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Athens, Panepistimiopolis Zografou, 15784 Athens, Greece. Hauptthemen laut MEDLINE: Antitubercular Agents, Lung. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative, European Union's Horizon 2020 Research and Innovation Programme, EFPIA and Global Alliance for TB Drug Development Non-Profit Organisation.
Abstract (Originalsprache)
Objectives
To develop physiologically based pharmacokinetic (PBPK) models for widely used anti-TB drugs, namely rifampicin, pyrazinamide, isoniazid, ethambutol and moxifloxacin lung pharmacokinetics (PK)—regarding both healthy and TB-infected tissue (cellular lesion and caseum)—in preclinical species and to extrapolate to humans.
Methods
Empirical models were used for the plasma PK of each species, which were connected to multicompartment permeability-limited lung models within a middle-out PBPK approach with an appropriate physiological parameterization that was scalable across species. Lung’s extracellular water (EW) was assumed to be the linking component between healthy and infected tissue, while passive diffusion was assumed for the drug transferring between cellular lesion and caseum.
Results
In rabbits, optimized unbound fractions in intracellular water of rifampicin, moxifloxacin and ethambutol were 0.015, 0.056 and 0.08, respectively, while the optimized unbound fractions in EW of pyrazinamide and isoniazid in mice were 0.25 and 0.17, respectively. In humans, all mean extrapolated daily AUC and Cmax values of various lung regions were within 2-fold of the observed ones. Unbound concentrations in the caseum were lower than unbound plasma concentrations for both rifampicin and moxifloxacin. For rifampicin, unbound concentrations in cellular rim are slightly lower, while for moxifloxacin they are significantly higher than unbound plasma concentrations.
Conclusions
The developed PBPK approach was able to extrapolate lung PK from preclinical species to humans and to predict unbound concentrations in the various TB-infected regions, unlike empirical lung models. We found that plasma free drug PK is not always a good surrogate for TB-infected tissue unbound PK.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Athens, Panepistimiopolis Zografou, 15784 Athens, Greece.
- Pharma-Informatics Unit, Athena Research Center, Artemidos 6 & Epidavrou, 15125 Marousi, Greece.
- Institute for Applied Computing "Mauro Picone", National Research Council (CNR), Via dei Taurini 19, 00185 Rome, Italy.
ORCID-Profile: Aristides Dokoumetzidis
Förderung
- Innovative Medicines Initiative
- European Union's Horizon 2020 Research and Innovation Programme
- EFPIA and Global Alliance for TB Drug Development Non-Profit Organisation
- Bill and Melinda Gates Foundation
- Bill & Melinda Gates Foundation
- European Union’s Horizon 2020 Research and Innovation Programme
Zitieren
APA
Karakitsios, E., & Dokoumetzidis, A. (2024). Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae109
Vancouver
Karakitsios E, Dokoumetzidis A. Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae109
BibTeX
@article{Karakitsios2024,
author = {Karakitsios, Evangelos and Dokoumetzidis, Aristides},
title = {Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae109}
}
EUVIMED